Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

00:00

SCR 109 and C. Diff

SCR 109 was well tolerated through 24 weeks, and the most common side effects were mainly gastrointestinal. Ibiza is a small molecule guanazine analog that competitively inhibits the DNA pool 3C enzyme. It's different from SCR 109 in that it is a C. diff episode treatment product, not prevention for recurrence. The microbiome pearls at the end of these novel C. diff agents are always just so fascinating.

Play episode from 52:11
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app